GSK, in a move in stark contrast to its strategy j

Quote:

---

GSK, in a move in stark contrast to its strategy just 6 years ago, is essentially building its pipeline in infectious diseases HIV, Oncology, and Immunology. This is such a unique combination and the top company that fits all 4 of those boxes is CytoDyn Inc.(OTCMKTS: CYDY).

---

The article discusses these 4 indication which GSK understands Leronlimab addresses. It also discusses $10. If it is for buyout, that is ridiculous. If it is for partnership, that is still ridiculous given HIV alone exceeds that.

But if it is "say" for HIV alone, I would take it. If it is for mTNBC alone, I would take it. If it is for NASH alone, I would take it.

But not in combination.